December 11, 2024 19:50 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | INDIA bloc to knock on Supreme Court's doors over alleged EVM manipulation during Maharashtra polls | 'Babri Masjid should be rebuilt in Bengal's Murshidabad': TMC MLA Humayun Kabir sparks row | Rajnath Singh calls on Russian Prez Vladimir Putin in Moscow, discusses bilateral defence cooperation | Police to investigate conspiracy angle in Mumbai bus accident that killed 7 | Mamata Banerjee should lead INDIA bloc: Lalu Prasad Yadav | Opposition moves no-confidence motion against VP Jagdeep Dhankar in RS

Bharat Biotech develops oral cholera vaccine Hillchol

Aug 28, 2024, at 06:46 am

Hyderabad:  Bharat Biotech International Limited (BBIL) has announced the launch of Hillchol (BBV131), a new single-strain Oral Cholera Vaccine (OCV) developed under a license from Hilleman Laboratories, which is funded by Merck, USA, and Wellcome Trust, UK. The vaccine aims to combat cholera.

Bharat Biotech starts clinical trials for TB vaccine

Mar 25, 2024, at 12:19 am

Hyderabad: Clinical trials for the new tuberculosis vaccine MTBVAC started in India on Sunday, a press release from Bharat Biotech said.

India gets its first covid nasal vaccine iNCOVACC manufactured by Bharat Biotech

Jan 26, 2023, at 10:11 pm

New Delhi/IBNS: Union Health Minister Dr Mansukh Mandaviya and Science and Technology Minister Jitendra Singh Thursday launched the world's first COVID-19 intranasal vaccine, iNCOVACC.

Bharat Biotech's intranasal COVID-19 vaccine to be launched on Republic Day

Jan 22, 2023, at 11:37 pm

Bhopal: Hyderabad-based vaccine maker Bharat Biotech is all set to launch its intranasal COVID-19 vaccine iNCOVACC on January 26, the company's chairman and managing director Krishna Ella said here on Saturday.

Govt approved Bharat Biotech's nasal anti-Covid vaccine: Reports

Dec 23, 2022, at 05:24 pm

New Delhi/IBNS/UNI: The central government has approved Bharat Biotech's nasal vaccine against Covid-19 amid the fresh scare of a surge in infections, media reports said.

Bharat Biotech's nasal Covid vaccine to be introduced as booster dose

Dec 23, 2022, at 04:32 am

New Delhi/IBNS: Bharat Biotech’s nasal Covid vaccine, iNCOVACC, will be introduced as a booster dose as the government gears up to avert a fresh wave of coronavirus, media reports said.

'Misleading' and 'fallacious': Govt's response to media reports alleging irregularities in Covaxin approval

Nov 17, 2022, at 10:39 pm

New Delhi/Hyderabad: The government has denied allegations of irregularities in giving approvals to Bharat Biotech for manufacturing Covaxin, India's first indigenously developed vaccine for Covid-19.

Bharat Biotech’s intra-nasal Covid-19 vaccine receives approval for emergency use in India

Sep 07, 2022, at 01:37 am

Hyderabad/UNI: Bharat Biotech International Limited (BBIL) Tuesday announced that iNCOVACC (BBV154), its intra-nasal vaccine against Covid-19, has received approval under restricted use in an emergency situation for ages 18 and above in India.

Covid19: WHO suspends UN supply for Bharat Biotech's Covaxin

Apr 03, 2022, at 07:45 pm

Geneva: The World Health Organisation (WHO) has suspended the supply of Covaxin made by Indian manufacturer Bharat Biotech to upgrade facilities and address deficiencies revealed in an inspection, media reports said.

Covishield and Covaxin get DCGI's conditional approval for sale in regular market

Jan 27, 2022, at 10:22 pm

New Delhi/IBNS: Covishield and Covaxin have been granted approval by drugs regulator Drugs Control Regulator General of India (DCGI) for sale in the regular market.

DCGI approves Covaxin shots for children above 12

Dec 26, 2021, at 04:38 am

Hyderabad/IBNS: Bharat Biotech's COVID-19 vaccine Covaxin received emergency approval from Drugs Controller General of India's (DCGI) for children between the ages of 12 and 18.

India's Bharat Biotech commences Covaxin exports

Nov 30, 2021, at 01:44 am

Hyderabad/UNI: Bharat Biotech International Limited on Monday announced it has commenced export of its Covid vaccine-Covaxin.

Hong Kong approves persons vaccinated with Covaxin for inbound travel

Nov 11, 2021, at 01:05 am

New Delhi/UNI: Travellers who have received both doses of Covaxin are now eligible for inbound travel to Hong Kong as the country has included the India-made COVID-19 vaccine into its list of approved vaccines.

Bharat Biotech's US partner files request for paediatric use of Covaxin

Nov 07, 2021, at 02:03 am

New Delhi/UNI: Ocugen Inc, Bharat Biotech's partner in the US and Canada for Covaxin, has submitted a request to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the Covid-19 jab for paediatric use.

Chinese vax took longer than COVAXIN to get approval, says WHO

Nov 04, 2021, at 06:20 am

New Delhi/IBNS: Covaxin did not take the longest to get the World Health Organization's (WHO) approval for Emergency Use Listing, according to Chief Scientist Dr Soumya Swaminathan.

Bharat Biotech's COVAXIN gets WHO approval

Nov 03, 2021, at 11:42 pm

New Delhi/IBNS: The World Health Organization (WHO) has given emergency use approval to Bharat Biotech's Covaxin, sources said Wednesday, clearing the way for the 'made-in-India' vaccine to get recognised by other nations and Indians inoculated with the shot would no longer need to self-quarantine or face restrictions when going abroad.

Bharat Biotech's Covaxin recommended for use in children below 18 years

Oct 13, 2021, at 03:23 am

New Delhi/IBNS: An expert panel on Tuesday recommended Bharat Biotech's Covaxin to be administered on children between the ages of two and 18.

Decision on Covaxin's clearance next: WHO

Oct 06, 2021, at 04:20 am

New Delhi/IBNS: The World Health Organisation (WHO) on Tuesday said it will announce its decision on clearance of India's indigenously developed Covaxin next week when the UN agency and an independent group of experts meet.

WHO's clearance to Bharat Biotech's Covaxin delayed: Reports

Sep 28, 2021, at 03:12 am

New Delhi/IBNS: The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the COVID vaccine developed in India by pharmaceutical company Bharat Biotech, media reports said.

WHO approval for Covaxin likely by month-end, says Niti Aayog

Sep 14, 2021, at 10:06 pm

New Delhi/IBNS: The World Health Organisation's emergency approval for indigenously made Covid-19 jab, Covaxin, can come by the end of September, said Dr VK Paul, chairman of the National Expert Committee on Vaccine Administration, according to media reports.

Bharat Biotech's 1st nasal COVID vaccine gets approval for phase 2 trial

Aug 14, 2021, at 02:49 am

New Delhi/IBNS: Bharat Biotech has received phase 2 human clinical trial nod for its nasal COVID vaccine, called BBV154, the Union Government informed on Friday.

Health Minister Mansukh Mandaviya meets WHO chief scientist to discuss Covaxin approval

Aug 13, 2021, at 05:47 am

New Delhi/IBNS: Union Health Minister Mansukh Mandaviya on Thursday met World Health Organisation (WHO) Chief Scientist Dr Soumya Swaminathan to hold discussion over the global health body's approval for Bharat Biotech's COVID-19 vaccine Covaxin.

Decision on Covaxin's emergency use listing in 4-6 weeks: WHO

Jul 11, 2021, at 02:11 am

New Delhi/IBNS: The World Health Organisation (WHO) will take a decision on emergency use approval for Bharat Biotech's Covaxin in the next four to six weeks, Soumya Swaminathan, the UN health body's chief scientist has said.

India reports 39,796 COVID-19 cases, 723 deaths in 24 hours

Jul 05, 2021, at 04:34 pm

New Delhi/IBNS: India, which is recovering from the second wave of COVID-19, on Monday reported over 39,000 new infections besides 723 deaths apparently due to the virus.

Covaxin's efficacy result will help getting WHO's approval : Govt expert body chief

Jul 04, 2021, at 02:04 am

New Delhi/IBNS: India-made Covaxin's recently published result on efficacy will help the vaccine in getting World Health Organisation’s (WHO) emergency approval, the chairperson of National Technical Advisory Group on Immunisation in India (NTAGI), Dr NK Arora said on Saturday.

Covaxin overall 77.8% effective against COVID-19, claims Bharat Biotech

Jul 03, 2021, at 06:54 pm

New Delhi/IBNS: Hyderabad-based biotechnology company Bharat Biotech has claimed its anti-COVID-19 vaccine, Covaxin, is 77.8% effective against the deadly virus.

Bharat Biotech says COVAXIN records 77.8 percent effectiveness against COVID-19 

Jul 03, 2021, at 02:30 pm

Hyderabad:  Bharat Biotech on Saturday claimed its created COVID-19 vaccine COVAXIN has shown 77.8 per cent effectiveness against the virus.  

Phase 3 trial data reveal Covaxin 77.8 pc effective against Covid19: Report

Jun 22, 2021, at 09:50 pm

New Delhi/IBNS: Indigenously made Covid-19 jab, Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against the deadly infection, according to data released from phase 3 trials conducted on 25,800 participants across India, according to media reports.

COVID-19 vaccine: Bharat Biotech submits Covaxin phase 3 trial data to DGCI, say reports

Jun 22, 2021, at 07:22 pm

New Delhi/IBNS: Hyderabad-based drug manufacturer Bharat Biotech has submitted the phase three clinical trial data of its anti-COVID-19 vaccine, Covaxin, to the Drug Controller General of India (DGCI), media reports said.

AIIMS Delhi to start screening 6-12 yrs children for Covaxin trial from Tuesday

Jun 15, 2021, at 05:57 am

New Delhi/IBNS: The All India Institute of Medical Sciences (AIIMS), New Delhi will begin the selection process of children in the age group of 6-12 years for the clinical trials of Bharat Biotech's Covaxin on Tuesday, said Dr Sanjay Rai, professor at the Centre for Community Medicine at AIIMS Delhi, said a media report.